Press Release
United States Antimony Corporation Announces Date For Release of Third Quarter and Nine Months Ended September 30, 2025 Financial and Operating Results
Conference Call and Webcast set for Wednesday, November 12, 2025, at 4:15 PM Eastern time "The Critical Minerals and ZEO Company" ~ Antimony, Cobalt, Tungsten, and Zeolite ~ Read More
Press Release
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to the U.S. FDA in July, the European Medicines Agency (EMA) application was submitted in September Rusfertide granted breakthrough designation for patients in Polycythemia Vera (PV) and the subject of four presentations including 52-week results of the VERIFY Phase 3 Study at ASH, the 67th Annual American Society of Hematology (ASH) meeting in December First patient dosed in the Phase 1 trial of PN-881, a first-in-class oral IL-17 peptide antagonist IND-enabling studies progressing as planned with triple-GLP/GIP/GCG agonists PN-477sc and PN-477o Oral hepcidin development candidate expected to be nominated by year end Cash, cash equivalents and marketable securities of $678.8 million as of September 30, 2025, anticipated to provide cash runway through at least end of 2028 Read More
Press Release
REMINDER: Initial Groundbreaking Results of Proof-of-Concept Study of Jaguar Health's Crofelemer for Treatment of Pediatric Intestinal Failure to be Presented November 8, 2025 at North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting
Results of ongoing investigator-initiated proof-of-concept trial of crofelemer in United Arab Emirates (UAE) demonstrate disease progression modification and reduction of total parenteral support (PS) in pediatric intestinal failure patients ranging between 12% to 37% Read More
Press Release
VSee Engages Philippine Health Leaders and Former VP Robredo in Southeast Asia expansion effort
VSee explores collaboration with Philippine Tuberculosis Society and former VP Leni Robredo to expand digital health innovation for Naga City starting with maternal health and primary care Read More
Press Release
Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update
89% of evaluable mipletamig patients achieve remission in combination therapy for frontline AML across two trials Introduces first trispecific molecules, APVO451 and APVO452, advancing therapies designed to overcome immune suppression in certain solid tumors Both molecules leverage Aptevo's unique use of the CRIS-7-derived CD3 binding domain, associated with favorable safety outcomes in the clinic; CD3 T-cell engager portfolio expanded to five Company raises $18.7 million in the third quarter, $4.1 million since quarter end, extends cash runway into 4Q26 Read More
Press Release
Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates
Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected revenue range to $1.6 - $2.0 billion Improves 2025 expected GAAP operating expenses by $0.7 billion to a range of $5.2 - $5.4 billion Increases 2025 expected year-end cash balance by $0.5 billion - $1 billion to a range of $6.5 - $7.0 billion Read More
Press Release
BK Technologies Reports Third Quarter 2025 Revenue Increase of 21% to $24.4 Million; Net Income Increases 46% to $3.4 Million
3Q25 gross margin of 49.9% compared with 38.8% in 3Q24 3Q25 GAAP diluted EPS of $0.87 compared with $0.63 in 3Q24 3Q25 non-GAAP diluted adjusted EPS1 of $1.27 compared with $0.71 in 3Q24 Record Cash Balance of $21.5 million; Financial debt-free balance sheet at September 30, 2025 Reiterating full year targets: high single-digit revenue growth, gross margin of 47%+, GAAP EPS of $3.15 per diluted share, and non-GAAP adjusted EPS of $3.80 per diluted share Read More
Press Release
